Serum 1,5-anhydroglucitol (GlycoMark™): A short-term glycemic marker

Diabetes Technology and Therapeutics

Volumn 5, Issue 3, 2003, Pages 355-363

  Buse, John B ^a   Freeman, Jennifer L R ^b   Edelman, Steven V ^c   Jovanovic, Lois ^d   McGill, Janet B ^e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b BioEmerge Partners Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SANSUM DIABETES RESEARCH INSTITUTE   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ANHYDROSORBITOL; GLUCOSE; HEMOGLOBIN A1C;

ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL PRACTICE; DIAGNOSTIC TEST; DISEASE CONTROL; DISEASE MARKER; GLUCOSE ASSAY; GLUCOSE BLOOD LEVEL; HEMODYNAMIC MONITORING; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; KIDNEY TUBULE; LIFESTYLE; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN ANALYSIS; URINARY EXCRETION;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; DEOXYGLUCOSE; ENVIRONMENTAL MONITORING; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYPERGLYCEMIA; ISOMERISM; JAPAN;

EID: 0037712960     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/152091503765691839     Document Type: Article

References (32)

1. Reichard P, Nilsson BY, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304-309.
2. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment if diabetes on the development and progression of the long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
3. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117.
4. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
5. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
6. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
7. American Diabetes Association: Tests of glycemia in diabetes. Diabetes Care 2003;26:106-108.
8. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002; 48:436-472.
9. Stahl M, Brandslund I, Jorgensen LG, Hyltoft Petersen P, Borch-Johnsen K, de Fine Olivarius N: Can capillary whole blood glucose and venous plasma glucose measurements be used interchangeably in diagnosis of diabetes mellitus? Scand J Clin Lab Invest 2002;62:159-166.
10. Bremer TJ, Edelman SV, Gough DA: Benchmark data from the literature for evaluation of new glucose sensing technologies. Diabetes Technol Ther 2001;3:409-418.
11. Gross TM, Bode BW, Einhorn D, Kayne DM, Reed JH, White NH, Mastrototaro JJ: Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use. Diabetes Technol Ther 2000;2:49-56.
12. Tierney MJ, Tamada JA, Potts RO, Jovanovic L, Garg S, Cygnus Research Team: Clinical evaluation of the GlucoWatch biographer: a continual, non-invasive glucose monitor for patients with diabetes. Biosens Bioelectron 2001;16:621-629.
13. Hom FG, Ettinger B, Lin MJ: Comparison of serum fructosamine vs glycohemoglobin as measures of glycemic control in a large diabetic population. Acta Diabetol 1998;35:48-51.
14. Edelman SV, Bell JM, Serrano RB, Kelemen D: Home testing of fructosamine improves glycemic control in patients with diabetes. Endocr Pract 2001;7:454-458.
15. Peterson CM, Jovanovic L: Glycosylated proteins in normal and diabetic pregnancy. Acta Endocrinol Suppl 1986;277:107-111.
16. Goldstein DE, Little RR: Monitoring glycemia in diabetes. Short-term assessment. Endocrinol Metab Clin North Am 1997;26:475-486.
17. Yamanouchi, T Akanuma Y: Serum 1,5-anhydroglucitol (1,5-AG): new clinical marker for glycemic control. Diabetes Res Clin Pract 1994;24(Suppl): S261-S268.
18. Stickle D, Turk, J: A kinetic mass balance model for 1,5-anhydroglucitol: applications to monitoring of glycemic control. Am J Physiol 1997;273:E821-E830.
19. Fukumura Y, Tajima S, Oshitani S, Ushijima Y, Kobayashi I, Hara F, Yamamoto S, Yabuuci M: Fully enzymatic method for determining 1,5-anhydro-D-glucitol in serum. Clin Chem 1994;40:2013-2016.
20. Tanabe T, Umegae Y, Koyashiki T, Kato Y, Fukahori K, Tajima S, Yabuuchi M: Fully automated flow-injection system for quantifying 1,5-anhydro-D-glucitol in serum. Clin Chem 1994;40:2006-2012.
21. Yamanouchi T, Akanuma Y, Toyota T, Kuzuya T, Kawai T, Kawazu S, Yoshioka S, Kanazawa Y, Ohta M, Baba S, Kosaka K: Comparison of 1,5-anhydroglucitol, HbA1c, and fructosamine for detection of diabetes mellitus. Diabetes 1991;40:52-57.
22. Kilpatrick ES, Keevilt BG, Richmond KL, Newland P, Addison GM: Plasma 1,5-anhydroglucitol concentrations are influenced by variations in the renal threshold for glucose. Diabet Med 1999;16:496-499.
23. Fujisawa T, Ikegami H, Tsutsui T, Kawaguchi Y, Ueda H, Shintani M, Nojima K, Kawabata Y, Ono M, Nishino M, Noso S, Yamada K, Babaya N, Ogihara T: Renal tubular function affects glycosuria-related urinary excretion of 1,5-anhydroglucitol. Diabetes Care 1999;22:863-864.
24. Emoto M, Tabata T, Inoue T, Nishizawa Y, Morii H: Plasma 1,5-anhydroglucitol concentration in patients with end-stage renal disease with and without diabetes mellitus. Nephron 1992;61:181-186.
25. Yamanouchi T, Akaoka I, Akanuma Y, Akanuma H, Miyashita H: Mechanism for acute reduction of 1,5-anhydroglucitol in rats treated with diabetogenic agents. Am J Physiol 1990;258:E423-E427.
26. Yamanouchi T, Minoda S, Yabuuchi M, Akanuma Y, Akanuma, H, Miyashita H, Adaoka I: Plasma 1,5-anhydro-D-glucitol as new clinical marker of glycemic control in NIDDM patients. Diabetes 1989;38:723-729.
27. Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, Akaoka I, Miyashita H: Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet 1996;347:1514-1518.
28. Kishimoto M, Yamasaki Y, Kubota, M, Arai K, Morishima T, Kawamori R, Kamada T: 1,5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care 1995;18:1156-1159.
29. Robertson DA, Rafique G, Robinson P, Bartlett K, Alberti KG: Serum anhydroglucitol as a diagnostic test for diabetes mellitus [abstract]. Diabet Med 1991;8:22A.
30. Robertson DA, Alberti KG, Dowse GK, Zimmet P, Tuomilehto J, Gareeboo H: Is serum anhydroglucitol an alternative to the oral glucose tolerance test for diabetes screening? The Mauritius Noncommunicable Diseases Study Group. Diabet Med 1993;10:56-60.
31. Tam WH, Rogers MS, Lau TK, Arumanayagam M: The predictive value of serum 1,5-anhydro-D-glucitol in pregnancies at increased risk of gestational diabetes mellitus and gestational impaired glucose tolerance. BJOG 2001;168:754-756.
32. Coster S, Gulliford MC, Seed PT, Powrie JK, Swaminathan R: Self-monitoring in type 2 diabetes mellitus: a meta-analysis. Diabet Med 2000;17:755-761.